Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia

A technology of ginseng diol saponin and ginsenoside, which is applied in the field of medicine, can solve problems such as insufficient curative effect of antiepileptic drugs, interference with the clinical treatment effect of ginseng or American ginseng, and reduced cognitive ability, so as to overcome insufficient curative effect and low safety, improve Anti-epileptic effect, effect of reducing toxic and side effects

Active Publication Date: 2012-10-24
ZHEJIANG UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, patients with epilepsy are often accompanied by various complications such as reproductive endocrine and neuroendocrine disorders and neuropsychiatric symptoms, which seriously affect the physical and mental health of patients and bring heavy burdens to families and society.
Existing antiepileptic drugs have many defects: for example, the existing antiepileptic drug multi-symptomatic treatment is mainly to control epileptic seizures, and it is ineffective for about 30% of epileptic patients; seizure recurrence often occurs after drug withdrawal; Antiepileptic drugs often have serious adverse reactions and side effects, prominently manifested as cognitive decline, mental disorders, reproductive endocrine and neuroendocrine disorders, and rashes, etc.
The application of the ginseng diol saponin component involved in the present invention in the preparation of drugs for the treatment of epilepsy is to provide a joint application with other anti-epileptic drugs, which can greatly enhance the anti-epileptic efficacy of existing anti-epileptic drugs and reduce the anti-epileptic effect. Drugs with their toxic and side effects, thereby overcoming the defects of insufficient curative effect and low safety of current antiepileptic drugs
[0007]2. Mixed use of ginseng diol saponins and triol saponins will interfere with the clinical therapeutic effects of ginseng or American ginseng
This makes it difficult to realize the medicinal value of ginseng or American ginseng or their total saponins for effective treatment of central excitatory or inhibitory diseases and symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia
  • Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia
  • Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Preparation of Panaxadiol Saponin Fraction-A (PDSF-A) from Radix Ginseng

[0052] 1. Isolation and Purification of Panaxadiol Saponin Fraction-A (PDSF-A) :

[0053]Ginseng rhizome medicinal material (8000 grams, sample-A, five kinds of ginseng diol saponins Rb contained therein 1 , Rc, Rb 2 , Rb 3 and Rd content and their total content are shown in Table 5) after pulverizing into a coarse powder, use 50% ethanol aqueous solution to percolate and extract until the extract is colorless, combine the percolate to recover ethanol under reduced pressure and freeze-dry to obtain the extract (678.6 gram). The medicinal extract was dissolved in 3000 milliliters of 45% ethanol aqueous solution, and the sample liquid was separated by macroporous adsorption resin (Diaion HP-20, 6000 grams) column chromatography, and first eluted with 45% ethanol aqueous solution until the eluent had no obvious saponin reaction, and then eluted with 70% ethanol aqueous solution un...

Embodiment 2

[0076] Example 2 Preparation of Panaxadiol Saponin Component-B (PDSF-B) from American Ginseng Rhizome

[0077] With American ginseng rhizome medicinal material (7000 grams, sample-B, five kinds of ginseng diol saponins Rb contained therein 1 , Rc, Rb 2 , Rb 3 and the content of Rd and their total content are shown in Table 5, and its HPLC collection is shown in Figure 1-3 ), adopt the same method of embodiment one to prepare the ginseng diol saponin component - B (PDSF-B, 101.3 g). HPLC analysis shows: PDSF-B also contains ginsenoside Rb 1 , Rc, Rb 2 , Rb 3 and Rd five kinds of ginsenosides, the total content of these five kinds of saponins is 91.60%, of which ginsenoside Rb 1 The highest content, followed by Rb 3 , Rd, Rb 2 and Rc; and Rb in Panaxadiol Saponin Fraction-B 1 / Rc / Rb 2 / Rb 3 / Rd content ratio and Rb in American ginseng rhizome (sample-B) 1 / Rc / Rb 2 / Rb 3 The content ratio of / Rd is basically the same (Table 5).

Embodiment 3

[0078] Example 3 Preparation of Panaxadiol Saponin Component-C ( PDSF -C)

[0079] Purchased commodity ginseng rhizome total saponins (sample-C 1 , its total saponin content ≥ 80%) and American ginseng stem and leaf total saponin (sample-C 2 , its total saponin content ≥ 80%) show through HPLC analysis, five kinds of ginseng diol saponins contained in these two kinds of total ginsenoside products have their own characteristics respectively, namely: Sample-C 1 Both contain ginsenoside Rb 1 , Rc, Rb 2 , Rb 3 and Rd, but Rb 3 The content is very low (see attached Figure 2-1 and Table 5); Sample-C 2 Contains mainly Rb 3 and Rd, and Rb 1 , Rc and Rb 2 The content is very low (see attached Figure 2-2 and Table 5). This implementation comprehensively utilizes these two samples (sample-C 1 and sample-C 2 ) as this raw material to prepare the ginsengdiol saponin active component of the present invention, especially to obtain the total content of five kinds of ginsengd...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a panaxadiol saponins fraction in preparing a medicine for preventing epilepsia. The component comprises the following main constituents: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc and ginsenoside Rd, and the medicine is prepared from active constituents in the single panaxadiol saponins fraction or from the active constituents in the single panaxadiol saponins fraction and other medicines. By taking one of five panaxadiol saponins: ginseng, American ginseng rhizome medicinal materials, ginseng stems and leaves, American ginseng stem and leaf medicinal materials and total extractives or total saponins of the ginseng, the American ginseng rhizome medicinal materials, the ginseng stems and leaves and American ginseng stem and leaf medicinal materials as a starting raw material independently or taking a mixture which consists of two or more than two different raw materials as the starting raw material comprehensively, the medicine is prepared by establishing the chromatographic separation and purification technology. According to the medicine prepared from the panaxadiol saponins fraction provided by the invention, an anti-epileptic effect can be greatly improved, and moreover, the toxic and side effects, especially dermatitis and intelligence toxicity, of traditional anti-epileptic medicines can be resisted, therefore, long-standing defects that the anti-epileptic medicines are not enough in curative effect and low in safety are overcome. The structural formula of the panaxadiol saponin is shown in specification.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the preparation of a panaxadiol saponins active component (hereinafter referred to as panaxadiol saponins fraction, Panaxadiol Saponins Fraction, PDSF) and a drug containing panaxadiol saponins fraction (PDSF) in the prevention and treatment of epilepsy Applications. More specifically, a method of comprehensively utilizing ginseng, American ginseng medicinal materials and their stems and leaves and their extracts or total saponins to prepare panaxadiol saponins; and panaxadiol saponins alone or with other substances including known antiepileptic The drug, especially the drug preparation made together with lamotrigine, is used in the treatment and prevention of epilepsy, epilepsy complications, and the synergistic and attenuating effects of existing antiepileptic drugs. Background technique [0002] 1. Existing antiepileptic drugs have many defects, and safer and more effective therapeutic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K36/258A61P25/08
Inventor 连晓媛郭欣张治针乔慧
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com